Human clinical trial data remains sparse, and the compound shares much of BPC-157's regulatory history: popular before 2023, restricted under Biden-era FDA action, and now under consideration for reinstatement
Briefly, the enzymatic reaction was initiated by incubating 15 g of protein from test samples (prepared without using protease inhibitor) with 20 M of a SIRT3 specific fluoro-substrate peptide, 200 M of NAD and 5 L of developer solution
This helps ensure reliable characteristics from batch to batch, supporting reproducible conditions in experimental settings
Generally, optimal IGF-1 levels range in the 230 to 270 nanogram per deciliter range
The largest human trial had only 16 test subjects, which means that if BPC-157 had, say, a 1% risk of a truly catastrophic side effect, a test like that would have a very small chance of catching it
It also acts as a cofactor for detoxification enzymes, including glutathione peroxidases, thus helping preserve cellular redox homeostasis